| Literature DB >> 17893993 |
Alberto Pignone1, Fabio Mori, Francesco Pieri, Andrea Oddo, Gianna Galeota, Ginevra Fiori, Angela Del Rosso, Federico Perfetto, Aureliano Becucci, Riccardo Livi, Alessio Tempestini, Chiara Benvenuti, Leonardo Gramigna, Roberto Fedi, Sergio Generini, Martina Minelli, Marina Cinelli, Serena Guiducci, Chiara Arcangeli, Maria Letizia Conforti, Pasquale Bernardo, Marco Matucci Cerinic.
Abstract
In systemic sclerosis (SSc), the involvement of the interstitium or vascular system of the lung may lead to pulmonary arterial hypertension (PAH). PAH is often asymptomatic or oligosymptomatic in early SSc and, when it becomes symptomatic, pulmonary vascular system is already damaged. Exercise echocardiography (ex-echo), measuring pulmonary artery pressure (PAP) during exercise and allowing to differentiate physiologic from altered PAP responses, may identify subclinical PAH. Our aims were (a) to evaluate by ex-echo the change of PAP in patients with SSc without lung involvement; and (b) to correlate PAP during exercise (ex-PAP) values to clinical and biohumoral parameters of PAH. Twenty-seven patients with limited SSc (ISSc) without interstitial lung involvement were studied. Patients underwent rest and exercise two-dimensional and Doppler echocardiography by supine cycloergometer. Systolic PAP was calculated using the maximum systolic velocity of the tricuspid regurgitant jet at rest and during exercise values of systolic PAP exceeding 40 mmHg at ex-echo were considered as abnormal, and biohumoral markers potentially related to PAH were assessed. Eighteen of 27 SSc patients presented an ex-PAP > 40 mmHg, while in 9 of 27 patients ex-PAP values remained < 40 mmHg (48.8 +/- 4.5 mmHg versus 36.2 +/- 3.1 mmHg; P < 0.001). Other echocardiographic and ergometric parameters, clinical tests, and biohumoral markers were not different in the two groups. Ex-PAP significantly correlated with D-dimer (P = 0.0125; r2 = 0.2029). Ex-echo identifies a cluster of SSc patients with subclinical PAH that may develop PAH. This group should be followed up and may be considered for specific therapies to prevent disease evolution.Entities:
Mesh:
Year: 2007 PMID: 17893993 DOI: 10.1196/annals.1422.031
Source DB: PubMed Journal: Ann N Y Acad Sci ISSN: 0077-8923 Impact factor: 5.691